Impedimed — Shareholder Meeting (October 2008)

13 slides from Impedimed's shareholder meeting presentation, Oct 31, 2008

Slide 1: ImpediMed reaffirms growth prospects for the US
ASX : IPD 31-Oct-2008 For personal use only ASX / PRESS RELEASE IMPEDIMED REAFFIRMS GROWTH PROSPECTS FOR THE US At today’s AGM, Chief Executive Officer, Greg Brown announces to shareholders that with the recent U.S. FDA clearance for the Company’s L- DexTM U400 device, the company was now in a posit
Slide 2: About ImpediMed
is the best way to assist in preventing and managing this important medical condition from progressing. Lymphoedema can be an extremely debilitating medical condition, and if not detected early, may progress to an irreversible condition. Treatment often involves exercise, compression bandaging, pump
Slide 3: For personal use only
AjJUO BSN FEUOSIOC! JOS
Slide 4: For personal use only
For personal use only 2
Slide 5: For personal use only
AjJUO BSN FEUOSIOC! JOS
Slide 6: For personal use only
AjJUO BSN FEUOSIOC! JOS
Slide 7: Coverage of lymphedema treatment
For personal use only GOVERAGE OF LYMPHEDEMA TREATMENT: (AR 4328 (Public Law 105-277)
Slide 8: For personal use only
AjJUO BSN FEUOSIOC! JOS
Slide 9: For personal use only
AjJUO BSN FEUOSIOC! JOS
Slide 10: For personal use only
For personal use only 8
Slide 11: For personal use only
For personal use only 9
Slide 12: For personal use only
For personal use only
Slide 13: Revenue, EBITDA and NPAT FY2008 vs FY2007
For personal use only Revenue EBITDA NPAT FY2008 2.213M 2.994M (7.639M) (9.754M) FY2007 1.195M 1.418M (6.628M) (10.126M) 11